These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30929977)

  • 41. Age- and gender-related differences in teicoplanin levels in paediatric patients.
    Strenger V; Hofer N; Rödl S; Hönigl M; Raggam R; Seidel MG; Dornbusch HJ; Sperl D; Lackner H; Schwinger W; Sovinz P; Benesch M; Urlesberger B; Urban C
    J Antimicrob Chemother; 2013 Oct; 68(10):2318-23. PubMed ID: 23702837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
    Wang JT; Liao HI; Wu Lin FL; Chang SC
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.
    Nakano T; Nakamura Y; Takata T; Irie K; Sano K; Imakyure O; Mishima K; Futagami K
    Int J Clin Pharm; 2016 Aug; 38(4):908-14. PubMed ID: 27125378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.
    Rouveix B; Jehl F; Drugeon H; Brumpt I; Caulin E
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2394-9. PubMed ID: 15215086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
    Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
    Ogami C; Tsuji Y; Muraki Y; Mizoguchi A; Okuda M; To H
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis.
    Papaioannou MG; Marinaki S; Pappas M; Stamatiadis D; Giamarellos-Bourboulis EJ; Giamarellou H; Stathakis C
    Int J Antimicrob Agents; 2002 Mar; 19(3):233-6. PubMed ID: 11932147
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
    Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
    Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Tatsumi S; Kimura T; Ikeuchi H; Uchino M
    J Infect Chemother; 2012 Jun; 18(3):296-302. PubMed ID: 22065089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study.
    Ullah MA; Shams-Ud-Dowla ; Maruf AA; Azad MA; Shohag MH; Sultana R; Latif AH; Hasnat A
    Clin Ther; 2010 Jul; 32(7):1419-26. PubMed ID: 20678688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. About the equivalence between different batches of a glycopeptide drug.
    Boix-Montañes A; Garcia-Arieta A
    Pharm Dev Technol; 2016 Aug; 21(5):642-5. PubMed ID: 25886080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The development of appropriate dosage of anti-bacterial and anti-fungal agents based on pharmacokinetics and pharmacodynamics].
    Matsumoto K
    Yakugaku Zasshi; 2012; 132(10):1171-7. PubMed ID: 23037703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus.
    Hagihara M; Umemura T; Kimura M; Mori T; Hasegawa T; Mikamo H
    J Infect Chemother; 2012 Feb; 18(1):10-6. PubMed ID: 21710160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.
    Tod M; Alet P; Lortholary O; Petitjean O
    J Pharmacokinet Biopharm; 1997 Dec; 25(6):695-712. PubMed ID: 9697078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Level of evidence for therapeutic drug monitoring of teicoplatin].
    Boulamery A; Venisse N; Le Guellec C;
    Therapie; 2011; 66(1):45-50. PubMed ID: 21466777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Glycopeptides (vancomycin, teicoplanin)].
    Furuta I; Kitahashi T
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():423-6. PubMed ID: 15658354
    [No Abstract]   [Full Text] [Related]  

  • 58. High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration.
    Lim SK; Lee SA; Kim CW; Kang E; Choi YH; Park I
    Hemodial Int; 2019 Jan; 23(1):69-76. PubMed ID: 30714672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The persistence of drug-induced fever by teicoplanin--a case report.
    Ochi H; Wada K; Okada H; Kohara N; Fujita T; Toda K; Sakamoto M; Seguchi O; Murata Y; Yanase M; Nakatani T
    Int J Clin Pharmacol Ther; 2011 May; 49(5):339-43. PubMed ID: 21543038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.
    Choi JS; Kim JM; Kim D; Kim SH; Cho H; Park HD; Lee SY; Kang CI; Kim YJ
    J Korean Med Sci; 2020 Nov; 35(46):e376. PubMed ID: 33258328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.